White House spat with Moderna intensifies with pressure building to donate more COVID vaccines: report Alvotech scores in AbbVie trade secrets case, but the Humira patent fight will stretch into next year New FDA chief set to be nominated by Biden, 9 months into his tenure White House funnels $1B into at-home COVID test makers, quadrupling monthly supply by December Healthcare Dealmakers—Intermountain, SCL Health's 33-hospital merger; Invitae's $325M Ciitizen acquisition Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D Startup aims to be a 'no-compromises' PBM, but the market may need convincing Pfizer requests FDA nod for COVID-19 shot in kids 5 to 11, but convincing parents might be a tough sell Gearing up to go public, Babylon CEO outlines the company's long-term game in digital health Cue Health taps Google Cloud to track down COVID variants and connect its portable tests Ellume at-home COVID tests recalled over false positive risk caused by manufacturing issue No sweat for Brickell: the biotech will submit its gel for FDA approval with 2 positive phase 3 trials Oculis snags Novartis head of ophthalmology Joanne Chang for CMO role Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy Featured Story | By Joseph Keenan Tensions are building between the White House and Moderna over the drugmaker’s apparent reluctance to commit to making more international donations of its COVID-19 vaccine available despite promises to supply millions of doses. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky Even as many biosimilar companies await their agreed-upon launch dates for their versions of the world’s bestselling drug—AbbVie's Humira—Alvotech is still busy battling the drug giant in court. This week, the company scored a big win. read more By Kevin Dunleavy After nearly nine months without a permanent FDA leader and after watching the agency withstand a torrent of criticism, President Joe Biden finally ready—almost—to announce a nominee for the beleaguered agency. read more By Andrea Park The billion-dollar investment is estimated to quadruple the total number of at-home, rapid tests available to Americans by December. Beginning that month, that number will reach 200 million tests per month, which will be available for purchase and distribution by government entities, employers and consumers alike. read more By Dave Muoio The return of Humana-Centene purchase rumors and more merger and acquisition news from the month of September. read more By Nick Paul Taylor Arch Venture Partners has taken the lid off its big bet on neuroscience. Having quietly put the startup together over the past 18 months, Thursday Arch unveiled Neumora Therapeutics—a biotech that starts life with $500 million, a collaboration with Amgen and a pipeline of eight prospects. read more By Anastassia Gliadkovskaya One startup is looking to disrupt the $370 billion prescription drug marketplace by offering a new "no compromises" approach to the traditional PBM model. Prescryptive acts as a PBM, negotiating prices directly with pharmacies. That allows the company to maintain fair rates, executives said. But pharmacists say many of these startups perpetuate the existing PBM model and don't address the need for more price transparency. read more By Kevin Dunleavy Amid some reluctance by parents to vaccinate their younger children, Pfizer and BioNTech have asked the FDA to authorize their COVID-19 shot for kids aged 5 to 11, the companies revealed on Thursday. read more By Heather Landi In the eight years since its launch in the U.K., Babylon has become a digital healthcare company to watch as it has expanded its reach from Rwanda all the way to Missouri. "I think somebody in healthcare will build one of the world’s largest and most valuable companies and there may be more than one. Every decision we make at Babylon is about that long-term game," Babylon founder and CEO Ali Parsa told Fierce Healthcare. read more By Conor Hale Cue plans to add real-time tracking of viral variants and sequencing data, bolstered by artificial intelligence programs to help identify newly emerging threats. read more By Andrea Park The recall comes just a few weeks after two of Abbott’s COVID tests became subject to a false-positive warning of their own, and less than a year after the Ellume test became the first over-the-counter self-test to receive emergency authorization from the FDA. read more By Kyle LaHucik Brickell Biotech reached statistical significance on all measures for both of its pivotal late-stage studies of a sweat gel. That gives the Colorado biotech the confidence to ask the FDA for approval in mid-2022. read more By Kyle LaHucik Joanne Chang departed Novartis after heading up worldwide medical affairs for ophthalmology for the past four years to be chief medical officer of Oculis. With a fresh set of eyes leading the medical affairs of the eye treatment biotech, Oculis will expand its presence in Hong Kong. read more By Angus Liu Yale University spinout Cybrexa Therapeutics has developed a peptide-drug conjugate that, instead of aiming for a specific antigen, targets the acidic environment of cancer cells to deliver a toxic payload. The drug improved the efficacy of checkpoint inhibitors in mouse models of cancer. read more |
